Delaying clinical disease onset would greatly reduce neurodegenerative disease burden, but the mechanisms influencing early preclinical progression are poorly understood. Here, we show that in mouse models of familial motoneuron (MN) disease, SOD1 mutants specifically render vulnerable MNs dependent on endogenous neuroprotection signaling involving excitability and mammalian target of rapamycin (mTOR). The most vulnerable low-excitability FF MNs already exhibited evidence of pathology and endogenous neuroprotection recruitment early postnatally. Enhancing MN excitability promoted MN neuroprotection and reversed misfolded SOD1 (misfSOD1) accumulation and MN pathology, whereas reducing MN excitability augmented misfSOD1 accumulation and accelerated disease. Inhibiting metabotropic cholinergic signaling onto MNs reduced ER stress, but enhanced misfSOD1 accumulation and prevented mTOR activation in alphaMNs. Modulating excitability and/or alpha-MN mTOR activity had comparable effects on the progression rates of motor dysfunction, denervation, and death. Therefore, excitability and mTOR are key endogenous neuroprotection mechanisms in motoneurons to counteract clinically important disease progression in ALS.
INTRODUCTION
Neurodegenerative diseases can involve decades-long preclinical phases of subtle pathologies (e.g., Reiman et al., 2004; Kok et al., 2009) followed by relentlessly progressing neurodegeneration. Any intervention that could delay clinical disease onset would have dramatic consequences on the burden of disease, but the mechanisms that influence early progression processes are poorly understood (Palop and Mucke, 2010; Saxena and Caroni, 2011) . The study of early disease mechanisms in vivo has been greatly aided by the availability of experimentally tractable animal models in which disease-related processes unfold according to specific cellular patterns and predictable temporal schedules. Nevertheless, dissecting disease-relevant causality relationships has remained challenging, mainly due to the difficulties inherent in discriminating underlying causes from adaptive consequences and harmless epiphenomena during slowly progressing early phases of disease in vivo. Because diseaserelated deficits might be neutralized initially through homeostatic and compensatory processes, we hypothesize that adaptive responses are likely to be predominant during early phases of disease. Accordingly, the identification and investigation of disease-relevant early dysfunction might benefit from a focus on candidate endogenous neuroprotection mechanisms that might compensate for mounting disease-related cellular malfunctions. Taking such an approach here, we focused on the early vulnerability of low-excitability fast-fatigable (FF) motoneurons (MNs) in amyotrophic lateral sclerosis (ALS) (Pun et al., 2006; Saxena et al., 2009; Kanning et al., 2010) and investigated how excitability might relate to the early progression of pathology and dysfunctions in mouse models of familial ALS. We provide evidence that excitability and mammalian target of Rapamycin (mTOR) together provide endogenous neuroprotection to familial amyotrophic lateral sclerosis (FALS) alpha-MNs and that a growing deficit in excitability-related signaling drives pathology and dysfunction in superoxide dismutase 1 (SOD1) mouse models of FALS.
Transgenic mice overexpressing FALS-associated human mutant SOD1 (mutSOD1) under the control of a human SOD1 promoter cassette have provided valuable animal models to investigate mechanisms of disease in ALS (Gurney et al., 1994; Boillé e et al., 2006; Kanning et al., 2010; Saxena and Caroni, 2011) . The mice exhibit characteristic MN disease features, including long presymptomatic phases of increasing cell specific pathology and dysfunction and rapidly progressing clinical phases leading to paralysis and death. MN pathology in SOD1-based FALS and in the corresponding rodent models closely resembles sporadic cases of ALS (Boillé e et al., 2006; Kanning et al., 2010) , establishing mutant mice as valid genetic models to investigate early mechanisms of disease in neurodegeneration. Notably, spinal alpha-MN pathology and dysfunction develops in the mice with remarkable temporal reproducibility, allowing the combination of data from individual mutant mice of different ages into virtual longitudinal studies (Pun et al., 2006; Saxena et al., 2009 ). These studies have provided evidence that in SOD1-based FALS models, low-excitability FF MNs innervating hind limb muscles abruptly prune their peripheral axonal arborizations within about 2 days (Pun et al., 2006) . Medium-excitability fatigue-resistant (FR) MNs disconnect from the periphery 30 days later, whereas highly excitable slow (S) MNs are resistant and only partially disconnect from target muscles when mice reach end-stage paralytic disease (Pun et al., 2006) . In each alpha-MN subpopulation, the selective denervation processes are preceded first by gradually increasing endoplasmic reticulum (ER) stress, followed by an unfolded protein response 20 days before denervation (Saxena et al., 2009) , and by axonal pathology during the last 2 weeks before denervation (Pun et al., 2006) . Taken together, these findings provided evidence for a higher vulnerability of lowexcitability FF MNs and a relatively higher resistance of highexcitability S MNs in FALS mice. Available clinical data are consistent with the notion that disease progression in ALS patients involves comparable differential vulnerabilities of lowand high-excitability alpha-MNs (Kanning et al., 2010) . Whether the low excitability of FF MNs might account for their higher vulnerability to degeneration has, however, remained unclear.
Early alterations in excitability have been reported in sporadic and familial ALS, as well as in mouse models of FALS (Bories et al., 2007; Vucic et al., 2008; Saxena and Caroni, 2011) . Reduced levels of astrocytic glutamate transporter and enhanced excitability have led to the hypothesis that excessive excitability and excitotoxicity might be major pathogenic factors in ALS (Rothstein, 1995 (Rothstein, -1996 Van Den Bosch et al., 2006) . On the other hand, studies of cultured spinal MNs have revealed a specific pathway affecting 50% of mutant MNs and to which wild-type MNs and mutant non-MNs are immune (Raoul et al., 2002; Kanning et al., 2010) . Those results have implicated excess MN cytosolic calcium and ER stress in FasL-and nitric oxide-induced cell death upon downregulation of the ER calcium sensor and chaperon Calreticulin in FALS MNs (Bernard-Marissal et al., 2012) . Calreticulin (Molinari et al., 2004) did not protect wild-type MNs from activation of the FasL pathway, suggesting that the vulnerability of alpha-MNs induced by mutSOD1 might specifically involve calcium and ER pathways (Bernard-Marissal et al., 2012) . Reduced Calreticulin levels were mainly detected in vulnerable FF MNs of tibialis anterior, but not in resistant MNs of soleus in presymptomatic SOD1(G93A) mice, suggesting that the specific calcium-related toxicity pathway also operates in FALS MNs in vivo (Bernard-Marissal et al., 2012) . The enhanced cytosolic calcium levels might reduce the excitability of MNs through the activation of calcium-dependent hyperpolarizing conductances (Miles et al., 2007) . Accordingly, MN excitability signaling in ALS might primarily be reduced, not enhanced. Furthermore, whereas ER stress in FALS (Kanekura et al., 2009; Saxena and Caroni, 2011) might be due to the accumulation of misfolded proteins, alternative scenarios (e.g., including a depletion of lumenal calcium in the ER) are also possible (Tu et al., 2006; Wang and Kaufman, 2012) . Taken together, these considerations have suggested contrasting potential scenarios of how alterations in excitability and ER stress might influence early phases of disease in ALS, but whether and how any of these have a role in disease progression has remained unclear.
Here, we investigated a possible role of excitability in disease progression in presymptomatic FALS mice. We first established antibodies against misfolded SOD1 (misfSOD1) as specific and sensitive cellular reagents to detect disease-relevant pathology in early presymptomatic FALS mice. We then provided evidence that disease-associated SOD1 mutants specifically render alpha-MNs dependent on endogenous neuroprotection signaling involving excitability and mTOR. During a protracted presymptomatic phase, inhibiting MN excitability was sufficient to induce comparable pathology and enhanced compensatory responses in all vulnerable alpha-MNs, suggesting that the relatively higher resilience of FR and S alpha-MNs to disease is related to their comparatively higher excitabilities. Enhancing MN excitability augmented neuroprotection pathways in FALS MNs. Modulating excitability or alpha-MN mTOR influenced the progression rates of motor dysfunction, muscle denervation, and death, providing evidence that excitability and mTOR are key endogenous neuroprotection mechanisms to counteract clinically important disease progression in FALS. Taken together, our results identify critical early dysfunction processes in FALS MNs, providing support to the notion that a focus on endogenous neuroprotection pathways in presymptomatic mice provides a valuable approach to unravel causal relationships between early disease-related dysfunctions and corresponding compensatory responses. Their elucidation might guide the elaboration of early therapeutic strategies in ALS.
RESULTS

Early Disease-Related Misfolded SOD1 Accumulation in Vulnerable MNs
To monitor relevant neuronal dysfunction in presymptomatic FALS mice, we first sought to establish specific early cellular disease-related markers. Because mutant SOD1 causes disease in the transgenic mice, we reasoned that misfSOD1 accumulation might provide an unbiased readout of the disease process. Accordingly, we investigated misfSOD1 immunoreactivity using conformation specific monoclonal antibodies D3H5 or A5C3, which specifically detect disease-associated epitopes of this ubiquitous cytosolic protein . AlphaMNs were identified as ventral horn cells, which were positive for vesicular acetylcholine transporter (VAChT) or choline acetyl transferase (ChAT) immunoreactivity, and were surrounded by brightly labeled VAChT-positive C-boutons, the presynaptic endings of cholinergic partition cells (Miles et al., 2007; Zagoraiou et al., 2009) . Most of the experiments were carried out in transgenic mice overexpressing moderate (TgG93Aslow; abbreviated as G93A-s) or high (TgG93Afast; abbreviated as G93A-f) levels of human SOD1(G93A) under the control of a human SOD1 minigene, but qualitatively comparable results were obtained with transgenic mice overexpressing a human SOD1(G85R) mutant.
From postnatal day (P) 7 on, but not yet at P1 (nor at embryonic day 15), we detected a distinct misfSOD1 signal specifically in a subpopulation of alpha-MNs in the lumbar spinal cord in mutant mice ( Figures 1A and 1B) . No misfSOD1 signals were detected in nontransgenic wild-type mice, or in transgenic mice overexpressing human wild-type SOD1 at any age (TgwtSOD1 mice; Figure 1A ). MN misfSOD1 signals remained confined to 40%-50% of lumbar spinal cord alpha-MNs until P55-60 (G93A-f) or P140-150 (G93A-s) ( Figure 1B ). Retrograde labeling experiments involving rhodamine-dextran applied locally to identified muscle compartments exclusively innervated by FF (lateral gastrocnemius, subcompartment l1), or mixed FR + S MNs (soleus) (Saxena et al., 2009 ) revealed that during this early presymptomatic phase, misfSOD1 specifically accumulated in FF MNs ( Figure 1C) . Consistent with the notion that misfolded mutant protein accumulation was initially specifically confined to the most vulnerable FF MNs, the distribution of the misfSOD1 signal among MNs closely resembled that of the ER chaperon binding immunoglobulin protein (BiP) ( Figure 1C ), which specifically accumulates in FF MNs in presymptomatic mice (Saxena et al., 2009) . Indeed, one of the antigens (A5C3) highlighted misfSOD1 accumulation closely codistributed with ER ( Figure 1A ), whereas D3H5 yielded more intense labeling signals that were distributed throughout the cytosol of MNs. After this protracted presymptomatic stage, and 5-10 days before an unfolded protein response (UPR) in FR MNs, the fraction of lumbar spinal cord alpha-MNs positive for misfSOD1 increased to >80% of total, thus including FR MNs ( Figure 1B ). Consistent with a specific disease association, MN misfSOD1 immunoreactivity signals and ventral spinal cord immunoprecipitation (IP)-western levels were reduced in early presymptomatic mutant mice (G93A-s, P105; i.e., in FF MNs) treated with the anti-ER stress reagent Salubrinal, which delays disease progression ( Figure 1D ; Saxena et al., 2009 ). The Salubrinal treatment also abolished the codistribution of A5C3 antigen with ER (not shown). We concluded that in the FALS disease models MN pathology as revealed by misfSOD1 accumulation is already detectable specifically in FF MNs at 1 week of age (but not before) and becomes detectable in FR MN shortly before the onset of the clinical phase.
Within a FALS Context alpha-MNs Depend on Excitability to Prevent Pathology
To investigate early mechanisms of disease in FALS, we then determined whether the higher relative vulnerability of FF MNs might be related to their lower excitability and whether reducing excitability might selectively compromise FALS alpha-MNs. In a first set of experiments, we treated FALS mice with nonparalyzing doses of the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and analyzed misfSOD1 accumulation patterns in mutant mice that had been exposed to CNQX during 1, 3, 5, or 20 days. Up to 5 days of treatments had no detectable effects in a grid test assay that measured muscle strength in wild-type or FALS mice, indicating that at these doses CNQX did not majorly affect MN firing activities (not shown). Nevertheless, the CNQX treatments had a dramatic impact on misfSOD1 accumulation and ER stress in alpha-MNs. In early presymptomatic mutant mice treated with CNQX for 1-3 days, misfSOD1 accumulation increased strongly in MNs, where it spread to most lumbar spinal alpha-MNs (Figure 2A ). In parallel, alpha-MNs exhibited massively elevated levels of ER chaperon BiP and of the UPR marker Pi-eIF2a (Figures 2A; Figure S1 available online). By contrast, the same treatments did not detectably enhance misfSOD1, BiP, or Pi-eIF2a levels in non-MNs in the spinal cord, or in other parts of the brain of SOD1 mutant mice ( Figure S1 ; not shown). Supporting the notion that reduced excitability augments MN pathology in mutant SOD1 mice, administration of the serotonin antagonists Ketanserin + Way (5-HT 1A/2A ) also rapidly augmented misfSOD1 accumulation and ER stress in alpha-MNs (Figure 2A ). N-methyl-D-aspartate (NMDA) receptor inhibition with AP5 was as effective as CNQX in augmenting alpha-MN misfSOD1 and ER stress, suggesting that the dramatic increase in pathology specifically in alpha-MN was due to reduced excitability-related signaling (Figure 2A ). Unlike short-term treatments during 1-5 days, prolonged treatments with CNQX during 20 days induced accumulation of misfSOD1 and BiP in a majority of neurons in the spinal cord and in the rest of the CNS in SOD1 mutant mice ( Figure S1 ). Even a prolonged attenuation of AMPA receptor transmission however failed to induce signs of UPR outside alpha-MNs ( Figure S1 ).
To determine whether alpha-MNs might be most affected by reduced excitability specifically in a disease context, we delivered CNQX to TgwtSOD1 mice that ubiquitously overexpress high levels of wild-type human SOD1 and only develop mild MN pathology late in life ( Figure S1 ). Up to five days of CNQX did not induce any detectable ER stress or accumulation of misfSOD1 in TgwtSOD1 alpha-MNs ( Figure S1 ). Twenty days of CNQX did induce a robust and closely comparable accumulation of BiP immunoreactivity in spinal MNs and non-MNs but only induced misfSOD1 accumulation and ER stress in few MNs in the TgwtSOD1 mice ( Figure S1 ). A 20 day regime of CNQX in nontransgenic wild-type mice again induced closely comparable accumulations of BiP in spinal MNs and non-MNs, albeit at lower levels than in TgwtSOD1 mice ( Figure S1 ). These results suggested that although chronic reduction of excitability during 20 days induces comparable ER stress in all neurons and in all genetic backgrounds, disease-related mutSOD1 greatly and specifically sensitizes alpha-MNs to adverse effects of reduced excitability.
To determine whether FALS neurons might be specifically sensitized to reduced excitability as opposed to being generally sensitized to stressors, we induced robust widespread ER stress in early presymptomatic FALS mice by intraperitoneal injections of Tunicamycin or Thapsigargin ( Figure 2B ). Two days later, drug-treated mice exhibited strongly elevated levels of the ER chaperon BiP in most spinal cord neurons ( Figure 2C ). By contrast, massively elevated levels of misfSOD1 were specifically induced in alpha-MNs, but were absent in other neurons (Figures 2B and 2C) . When tgwtSOD1 mice were subjected to the same treatment, misfSOD1 accumulation was much less pronounced than in FALS mice, but it was again restricted to alpha-MNs ( Figures 2B and 2C ). Interestingly, cerebellar Purkinje cells also exhibited selective misfSOD1 accumulation upon enhanced ER stress in FALS and tgwtSOD1 mice ( Figure 2B ), but they lacked detectable misfSOD1 signals in FALS mice even upon 5 days of CNQX treatment (not shown, but see Figure S1 for 20 day CNQX treatment). These results revealed that intense ER stress is not sufficient to induce misfSOD1 accumulation in most FALS neurons and provided evidence for the existence of a specific relationship between SOD1-related pathology, excitability and stressors selectively in alpha-MNs (Ezzi et al., 2007; Pokrishevsky et al., 2012) .
Excitability Modulates Disease Progression in FALS
To investigate whether enhanced excitability might negatively modulate the accumulation of FALS-related pathology in MNs, we analyzed mutant SOD1 mice treated with the receptor agonist AMPA. AMPA greatly reduced the accumulation of misfSOD1 in alpha-MNs of presymptomatic and symptomatic mutant SOD1 mice ( Figure 3A ). Furthermore, AMPA significantly reduced the accumulation of ER stress and UPR markers in presymptomatic mice, albeit not at more advanced phases of disease ( Figure 3A ). Interestingly, AMPA was comparably effective in reducing misfSOD1 accumulation when drug administration regimes were started at early or late presymptomatic stages ( Figure 3A ), suggesting that misfSOD1 accumulation in FALS alpha-MNs is a dynamic process, which can be reversed by enhanced excitability. Notably, AMPA counteracted the downregulation of Calreticulin in FF MNs ( Figure 3B ), the ER chaperon and lumenal calcium sensor, which is a disease-specific trigger of dysfunction and death in selectively vulnerable FALS alphaMNs (Bernard-Marissal et al., 2012) . Taken together, these results provided evidence that although reduced excitability specifically aggravates disease-related pathology in FALS alpha-MNs, enhanced excitability can specifically protect the same vulnerable alpha-MNs.
To investigate whether AMPA promotes neuroprotection pathways in presymptomatic FALS MNs, we monitored accumulation levels of the calcium-dependent neuroprotection proteins GADD45b, DREAM, and Btg2 (Zhang et al., 2009 ) in wild-type and G93A-f mice. MN GADD45b immunoreactivity was elevated in FALS compared to wild-type MNs ( Figure 3C ). Daily AMPA treatments from P25 to P31 enhanced MN GADD45b signals, and this effect was much more pronounced in FALS than in wild-type MNs ( Figure 3C ). Conversely, CNQX reduced MN GADD45b, and the effect of CNQX was more pronounced in wild-type MNs ( Figure 3C ). AMPA thus enhances the levels of endogenous neuroprotection protein GADD45b in MNs and this upregulation is specifically potentiated in FALS MNs. In contrast to GADD45b, DREAM levels were substantially reduced in FALS MNs compared to wildtype values ( Figure 3C ). AMPA restored FALS MN DREAM signals to nearly wild-type values, whereas it did not affect DREAM signals in wild-type MNs ( Figure 3C ). Likewise, CNQX substantially reduced DREAM signals in FALS, but did not affect DREAM signals in wild-type MNs ( Figure 3C ). Endogenous neuroprotection mechanisms involving DREAM are thus specifically downregulated in FALS MNs, where they are rescued by AMPA and further reduced by CNQX. Finally, Btg2 levels were markedly elevated in FALS MNs, suggesting activation of endogenous neuroprotection pathways ( Figure 3C ). AMPA restored FALS MN Btg2 to nearly wild-type values, whereas CNQX had no detectable effect ( Figure 3C ). Taken together, these results provided evidence that AMPA enhances neuroprotection specifically in FALS MNs as revealed by potentiated GADD45b enhancement and by restored FALS MN DREAM levels. The results further suggested that activation of additional neuroprotection pathways in FALS MNs led to elevated Btg2 levels, which were restored to nearly wild-type values by AMPA.
We next determined whether altering AMPA receptor activation also affects clinically relevant disease progression in mutant SOD1 FALS mice. Mutant mice were treated with CNQX or with AMPA from P40 (G93A-s) or P20 on (G93A-f), and we compared sustained force (grid test), peripheral denervation, and survival in drug-treated and vehicle-treated cohorts. The treatments did not detectably affect total hSOD1 or total pan-SOD1 (mouse plus human) signals in MNs (not shown, but see below). CNQX accelerated force loss (not shown), denervation ( Figure 3E ) and death ( Figure 3F ) by 30 days in mutant SOD1 mice. Prolonged treatments with CNQX did not induce noticeable force loss or denervation in tgWTSOD1 mice, further supporting the notion that reduced excitability aggravates pathology specifically within a disease background (not shown). Conversely, AMPA markedly improved force (Figure 3D) , delayed FR and S denervation ( Figure 3E ), and extended survival by 20-35 days ( Figure 3F ) in mutant SOD1 mice. Although denervation by resistant FR and S MNs was substantially delayed by the AMPA receptor treatments, denervation by FF MNs was not detectably affected (not shown, but see below). Likewise, although AMPA receptor activation or inhibition modified the timing of peripheral denervation and clinical manifestations of disease, the same treatments did not alter the specific patterns of progressive deficits involving first the least excitable FF MNs, then FR MNs, and finally the most excitable S MNs. Taken together, these results provided evidence that the status of chronic AMPA receptor activation can modulate disease progression in FALS mice. The results further suggested that FALS FF MNs might be least effective in harnessing neuroprotection through excitability.
Cell Autonomous Neuroprotection by Excitability in FALS MNs
To determine whether excitability specifically of MNs influences misfSOD1 accumulation and disease-related pathology in FALS mice we carried out pharmacogenetic experiments in vivo. Floxed pharmacologically selective actuator module (PSAM) either coupled to 5HT3-receptor (PSAM-Act) for neuronal depolarization or to glycine-receptor (PSAM-Inh) for neuronal hyperpolarization (Magnus et al., 2011) was expressed unilaterally in lumbar spinal cord alpha-MNs (ChAT-Cre mice) or Parvalbumin-positive interneurons (PV) (PV-Cre mice) using AAV9 viral vectors. Expressed channels were then activated using a specific ligand (Magnus et al., 2011) . Unilateral channel expression in individual MNs or PV neurons, including PSAM-expressing PV boutons adjacent to alpha-MNs, could be readily detected with fluorescently labeled a-Bungarotoxin ( Figure 4A ). Enhancing MN excitability or reducing PV neuron excitability (disinhibition of MNs) specifically reduced misfSOD1 and BiP accumulation in ipsilateral FALS alpha-MNs ( Figures 4B and  4C) . A detailed analysis revealed that reduced misfSOD1 and BiP accumulation were specifically associated with individual PSAM-expressing MNs within ipsilateral ventral horn (not shown). Total MN hSOD1 signals were not affected in these experiments ( Figure 4C ). Conversely, reducing MN excitability specifically enhanced misfSOD1 and BiP accumulation in ipsilateral FALS alpha-MNs ( Figures 4B and 4C) . In control experiments, the same pharmacogenetic treatments did not affect ER stress markers in wild-type MNs (not shown). In parallel to reducing misfSOD1 and BiP accumulation, MN activation specifically enhanced levels of neuroprotective proteins GADD45b and DREAM and decreased Btg2 levels in ipsilateral FALS MNs (Figure 4D) . Finally, prolonged pharmacogenetic activation of FALS MNs specifically reduced pEIF2a accumulation (UPR) and delayed muscle denervation by FF MNs ( Figure 4E ). Taken together, these results provided evidence that enhanced excitability of MNs cell autonomously promotes neuroprotection and delays disease manifestations in FALS MNs.
Altered Signaling to CREB in Affected FALS MNs
To investigate whether intracellular signaling related to excitability might be altered in FALS alpha-MNs, we analyzed MN levels of phosphorylated (Ser133) cAMP response elementbinding protein (pCREB), an activity-sensitive readout for alterations in calcium, MAP-kinase, and cAMP pathways in neurons (Greer and Greenberg, 2008) . In young presymptomatic FALS mice, pCREB levels within MNs were markedly reduced compared to wild-type mice ( Figure 5A ). Retrograde labeling revealed that FF MNs exhibited highest pCREB levels among alpha-MNs in resting wild-type mice and that it was specifically FF MNs that exhibited lower pCREB levels in resting FALS mice ( Figure 5A ). Exercise failed to enhance pCREB levels in FALS MNs (Figure 5A ), suggesting diminished excitation-related signaling to CREB in FALS MNs. AMPA reduced pCREB levels in MNs of wild-type and mutant SOD1 mice to comparable levels ( Figure 5A ). Wild-type and mutant mice treated with the serotonin agonists quizapine (5-HT 2A ) and 8OH-DPAT (5-HT 1A/7 ) also exhibited comparable and substantially reduced pCREB levels in alpha-MNs ( Figure 5A ), suggesting that enhanced excitability can neutralize pCREB differences between wild-type and FALS alpha-MN, and reduced pCREB levels in FALS FF MNs at rest might reflect enhanced excitability in these most vulnerable alpha-MNs in early presymptomatic mice.
Enhanced Excitability Connectivity onto FALS MNs
To investigate whether endogenous alterations in excitability connectivity might counteract disease progression in FALS MNs, we analyzed the distribution of synapses that control the excitability of alpha-MNs in FALS mice. We did not detect obvious alterations in the sizes or densities of sensory afferent VGlut1 puncta onto MN somas and proximal dendrites (not shown). By contrast, we found that ventral horn gephyrin puncta densities were 60%-65% of wild-type values ( Figure 5B ), suggesting a major reduction of inhibitory synapse densities onto mutant MNs at early stages of disease. Furthermore, ventral spinal cord densities of serotonergic boutons, which positively modulate MN excitability and motor output, were significantly elevated in presymptomatic SOD1 mutant mice ( Figure 5C ). Finally, metabotropic cholinergic C-bouton puncta onto mutant MNs, which also positively modulate MN excitability, were on average substantially larger than in wild-type mice ( Figure 5D ; see also Pullen and Athanasiou, 2009 ). These observations suggested the presence of a larger excitability drive onto MNs in early presymptomatic mutant spinal cords.
A more detailed examination of C-bouton size distributions onto individual MNs suggested that only a fraction of the MNs were contacted by enlarged C-boutons in the mutant mice. Retrograde labeling experiments revealed that in wild-type mice C-boutons contacting FF MNs were larger than those contacting FR or S MNs (not shown) and that it was specifically the C-boutons onto MNs with high BiP signals that were further enlarged in young mutant FALS mice ( Figure 5E ). An analysis of C-bouton sizes versus age revealed that disease-related enlargement was confined to FF MNs up to their denervation time in G93A-f and G93A-s mice, when it then extended to a majority of alpha-MNs (not shown). Consistent with a recent report (Herron and Miles, 2012) , and with a somewhat more severe progression of disease in male FALS mice, C-bouton enlargements appeared with an 8-10 day delay and were less pronounced in female FALS mice (not shown). CNQX treatment produced C-bouton enlargements in a majority of alpha-MNs in young presymptomatic FALS mice ( Figure 5F ), supporting the notion that delayed C-bouton enlargement and pathology in FR MNs were related to their higher intrinsic excitability compared to FF MNs. Taken together, these results were consistent with the notion that in FALS mice enhanced excitability connectivity might be induced to provide more effective neuroprotective signaling to vulnerable FALS alpha-MNs.
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Neuroprotection in FALS Mediated through Cholinergic C-Bouton Signaling
To investigate endogenous neuroprotective mechanisms that counteract disease progression in FALS mice, we focused on the possible role of C-bouton-mediated neurotransmission onto MNs. Metabotropic transmission at these perisomatic synapses leads to inhibition of calcium-dependent potassium channels, possibly counteracting inhibitory effects of enhanced cytosolic calcium on alpha-MN excitability (Miles et al., 2007; Zagoraiou et al., 2009 ). Furthermore, these large cholinergic boutons are associated with abundant ER membrane systems closely associated with the postsynaptic membrane, and their enlarged sizes onto the most vulnerable MNs suggested a specific role early in disease (Pullen and Athanasiou, 2009 ). To determine whether the larger size of C-boutons onto vulnerable MNs of mutant SOD1 mice might occur in response to a deficit in excitability signaling, we analyzed C-bouton size distributions in mice treated with CNQX ( Figure 6A ). Treating wild-type mice with CNQX produced a substantial and apparently general enlargement of C-boutons ( Figures 5F and 6A) , whereas AMPA induced a general shrinkage of C-boutons in wild-type mice (Figure 6A) . By contrast, reducing ER stress with Salubrinal or enhancing ER stress with Tunicamycin did not influence Cbouton sizes in wild-type or FALS mice ( Figure 6A ) suggesting that C-bouton sizes adjusted specifically to excitability signaling deficits and not to disease-related ER stress.
To investigate the role of neurotransmission through Cboutons in disease progression, we treated mice with either an antagonist (Methoctramine) or agonist (Oxotremorine) of the type-2 metabotropic ACh receptor, which specifically mediates cholinergic transmission at C-boutons (Miles et al., 2007) . Administration of Methoctramine in early presymptomatic FALS mice produced a dramatic increase and spread of misfSOD1 accumulation to most spinal alpha-MNs ( Figure 6B ). Surprisingly, methoctramine at the same time strongly reduced ER stress and delayed UPR ( Figure 6B ). Methoctramine initially delayed force loss in presymptomatic mutant mice ( Figure 6C ), but it later accelerated denervation ( Figure 6C ), loss of force (Figure 6C) and death (not shown). Conversely, Oxotremorine enhanced BiP signals in MNs (Figure 6D ), enhanced UPR in FF MNs (not shown), but did not significantly influence the accumulation of misfSOD1 in FALS MNs ( Figure 6D ). Oxotremorine delayed denervation ( Figure 6E ) late loss of force and death (see below) in mutant SOD mice. Although indirect effects of these pharmacological experiments targeting M2 receptors cannot be excluded, the results were consistent with the notion that C-bouton transmission influences disease-related pathology, both in low-excitability FF MNs with enlarged C-boutons, as well as in more resistant FR and S MNs without enlarged C-boutons. In addition, the results revealed a dramatic and unexpected dissociation between the accumulation of misfSOD1 and ER stress in FALS MNs, suggesting that metabotropic cholinergic transmission might influence additional pathways in FALS MNs, accounting for reduced misfSOD1 accumulation and neuroprotection.
Central Neuroprotective Role of mTOR in FALS MNs
In a search for additional neuroprotective pathways that might be activated by metabotropic cholinergic transmission, we noticed that phospho-S6 (pS6) immunoreactivity was specifically elevated in those MNs that exhibited elevated levels of misfSOD1 and BiP ( Figure 7A ). The elevated pS6 levels reflected enhanced activation of mTOR in those vulnerable MNs, as demonstrated by suppression upon administration of the mTOR inhibitor Rapamycin (Figure 7B ), by the concomitant accumulation of the specific mTOR pathway markers p4EBP and pTOR (not shown) and by increased levels of the autophagy markers ATG6/Beclin ( Figure 7B ) and LC3 (not shown) in FALS MNs upon Rapamycin treatment. FALS MN Btg2 upregulation was abolished in Rapamycin-treated mice ( Figure 7B ), indicating that it depended on mTOR activation. Elevated pS6 and Btg2 signals were detected in FF MNs from the earliest time points included in our analysis (P15), and increased gradually, in close correspondence with misfSOD1 and BiP, and with larger C-boutons, first exclusively in FF and later also in FR and S MNs (Figure 7C) . Methoctramine suppressed and oxotremorine enhanced pS6 (and Btg2, not shown) accumulation in vulnerable MNs ( Figure 7D ), suggesting that mTOR activation in FALS MNs specifically depended on C-bouton transmission. MN pS6 levels were substantially enhanced by CNQX, suggesting that the Cbouton-mTOR-Btg2 pathway might be activated in FALS MNs in response to a deficit in neuroprotection signaling ( Figure 7E ).
To determine whether mTOR protects vulnerable MNs against pathology induced by mutant SOD1, we chronically treated FALS mice with Rapamycin and analyzed disease markers in vulnerable MNs. Rapamycin produced a dramatic accumulation of misfSOD1, as well as UPR in most spinal alpha-MNs of presymptomatic mutSOD1 mice ( Figure 8A ) and a pronounced downregulation of Calreticulin in spinal MNs of presymptomatic FALS mice ( Figure 8B ), suggesting that the mTOR pathway is critically important to counteract disease-specific pathology in FALS NMs. By contrast, and consistent with the notion that a disease setting involving mutSOD1 specifically renders alpha-MNs dependent on neuroprotection involving mTOR, Rapamycin did not induce ER stress in alpha-MNs of wild-type mice ( Figure S1 ).
To determine whether endogenous mTOR activation protects against clinical aspects of disease progression in mutant SOD1 mice, we compared cohorts of mice treated with Rapamycin or vehicle. Rapamycin produced a complete denervation of soleus muscle at P75 in G93A-f mice ( Figure 8C ), indicating that denervation of FR and S MNs in the mutant mice was accelerated by 20 and 60 days, respectively. Furthermore, treating mutant SOD1 mice with Rapamycin decreased survival by 30 days (not shown; N = 5 mice each, p < 0.001). By contrast, and consistent with the notion that vulnerable MNs depend on active mTOR for neuroprotection specifically within a FALS setting, chronic treatment of wild-type mice with Rapamycin did not detectably affect peripheral innervation ( Figure S1 ) or survival (not shown). Taken together, these results suggested that metabotropic cholinergic transmission promotes distinct processes in MNs, with opposite impacts on MN pathology in a FALS context; these include neuroprotective mTOR activation and pathologyenhancing ER stress activation.
To determine whether mTOR activation downstream of metabotropic cholinergic transmission is important to protect MNs in disease, we analyzed mutant SOD1 mice treated chronically with Oxotremorine to stimulate mTOR and at the same time with Salubrinal to reduce the concomitant elevation of ER stress. The dual treatment dramatically delayed pathology and clinical manifestations in FALS mice. Thus, Oxotremorine + Salubrinal greatly reduced the accumulation of misfSOD1 ( Figure 8D ), reduced ER stress markers ( Figure 8D ), and delayed UPR (not shown), while preserving elevated levels of pS6 and Btg2 (not shown) in FALS MNs. In parallel, Oxotremorine + Salubrinal delayed peripheral denervation of FR and S MNs by at least 40 days, substantially counteracted force loss, and extended survival by 50 ± 9 days (N = 8 mice each, p < 0.0001) in the FALS mice ( Figure 8E ). 
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DISCUSSION
We have investigated early mechanisms of disease in SOD1 mouse models of FALS, focusing on endogenous neuroprotection mechanisms and the selective vulnerability of alpha-MNs. We provide evidence that disease-associated SOD1 mutants specifically render vulnerable MNs dependent on endogenous neuroprotection signaling involving MN excitability and mTOR. The most vulnerable low-excitability FF MNs exhibited evidence of pathology and neuroprotection recruitment from P7-14 on, which included increasing accumulation of misfSOD1 and enhanced mTOR activation. Enhancing MN excitability was sufficient to reverse misfSOD1 accumulation, whereas blocking metabotropic cholinergic signaling greatly enhanced misfSOD1 accumulation in alpha-MNs but reduced ER stress, suggesting that ER stress is not directly caused by misfSOD1 accumulation in FALS ( Figure 8F ). During a protracted presymptomatic phase, inhibiting excitability was sufficient to induce comparable pathology and enhanced neurocompensatory responses in most alpha-MNs, but not in other neurons in FALS mice, suggesting that the relatively higher resilience of FR and S alpha-MNs to disease is related to their comparatively higher excitabilities. Modulating excitability and/or alpha-MN mTOR influenced the progression rates of motor dysfunction, muscle denervation, and death, providing evidence that excitability and mTOR are key endogenous mechanisms to counteract clinically important disease progression in FALS (Figures 8F and 8G) . In the following sections, we discuss the main implications of these results and how they relate to those of previous studies addressing mechanisms of disease in neurodegeneration.
Selective Vulnerability of MNs to SOD-Mediated Neurodegeneration
Our results provide insights as to how MNs are selectively affected in FALS. Because most neurons accumulated misfSOD1 in FALS mice treated chronically with CNQX, but not in tgwtSOD1 mice, our results do not support the notion that this ubiquitously expressed mutant protein specifically affects alpha-MNs. Instead, our results suggest that SOD1 mutants alter aspects of homeostasis signaling related to excitability that are particularly consequential in vulnerable alpha-MNs ( Figure 8G ). Thus, short-term global inhibition of excitability during 1-3 days in mutant SOD1 FALS mice induced misfSOD1 accumulation and a robust UPR in most alpha-MNs, but not in other neurons in the spinal cord or in the brain. Furthermore, direct pharmacogenetic inhibition of excitability in MNs enhanced misfSOD1 accumulation and ER stress in those MNs. Taken together, our findings suggest that in mutSOD1 models of FALS vulnerable alpha-MNs are highly sensitized to cellular stressors and specifically depend on endogenous excitability and mTOR to delay clinically relevant disease progression ( Figure 8G ). This sensitization model of motoneuron disease pathophysiology suggests that the signaling and homeostasis networks of vulnerable alpha-MNs include specific features that render these neurons more susceptible to neurodegeneration pathways (Kanning et al., 2010; Saxena and Caroni, 2011) . These might be closely linked to calcium homeostasis processes (von Lewinski and Keller, 2005; Kanning et al., 2010; BernardMarissal et al., 2012) . The model is reminiscent of findings in Parkinson's, Alzheimer's, and Huntington's disease studies, in which specific neuronal vulnerabilities have also been related to selective degeneration (Bezprozvanny and Mattson, 2008; Mosharov et al., 2009; Saxena and Caroni, 2011; Gleichmann et al., 2012) . As discussed below, alterations in calcium fluxes and excitability signaling might be a common pathogenic signature of neurodegenerative diseases.
Although our results suggest that the particular vulnerability of alpha-MNs to neurodegeneration involves excitability-related pathways, the specific homeostasis and signaling pathway features that account for this higher vulnerability remain to be determined. The conclusions of our study in FALS mice are consistent with those of previous studies reporting that vulnerable FALS MNs in vitro are specifically susceptible to cell death induced by Fas-ligand and nitric oxide, whereas wild-type MNs or other FALS neurons are not (Raoul et al., 2002) . Like the present study, those studies concluded that FALS MNs acquire a vulnerability to specific stressors not present in wild-type MNs. Those studies further provided evidence that elevated cytosolic calcium levels and loss of Calreticulin are critical determinants of enhanced vulnerability in cultured FALS MNs, leading to ER stress and cell death (Bernard-Marissal et al., 2012) . We detected similar Calreticulin downregulation correlated with advancing pathology and inhibited by excitability and mTOR in our study, consistent with the notion that imbalances in alpha-MN calcium homeostasis might underlie disease progression in FALS mice ( Figure 8G ).
Endogenous Neuroprotection Analysis Reveals Mechanisms of Disease Progression
Our longitudinal study in FALS mice provides experimental evidence as to endogenous neuroprotection mechanisms that delay pathology and dysfunction in FALS and suggests that a deficit in excitability signaling in vulnerable alpha-MNs might (G) Proposed model of vulnerable MN sensitization to stressors and role of endogenous neuroprotection mechanisms in FALS. Endogenous neuroprotection processes in blue, against gray background. CRT: Calreticulin; Glu, 5HT, GABA/Gly, C-boutons: synaptic pathways promoting endogenous neuroprotection. Metabotropic cholinergic activation also enhances ER stress, and enhanced excitability might also augment neurotoxicity. See also Figure S2 . be a key disease-driving factor in ALS. Contrary to some previous reports, our findings suggest that the well-documented early hyperexcitability of MNs in ALS (Vucic et al., 2008; Piotrkiewicz and Hausmanowa-Petrusewicz, 2011; Martin and Chang, 2012) might represent an adaptive response to boost neuroprotective signaling in alpha-MNs (see also Gordon et al., 2010) . Indeed, initial hypoexcitability of FALS MNs has been reported by some studies (Bories et al., 2007) . At the same time, however, hyperexcitability might contribute to aggravate disease loads on MNs through excitotoxicity mechanisms (Rothstein, 1995 (Rothstein, -1996 Van Den Bosch et al., 2006; Gleichmann et al., 2012) . Our results further provide a conceptual framework to account for the particularly high vulnerability of low-excitability FF MNs to disease (Pun et al., 2006; Saxena et al., 2009 ). The results suggest that in addition to being affected earliest in disease, high-threshold FF MNs might be less effective in coupling excitability to neuroprotection, leading to less effective delay of denervation with AMPA or Oxotremorine + Salubrinal in FF MNs. Comparable vulnerability sequences involving first FF and last S MNs have also been reported for the juvenile motoneuron disease SMA and for motoneuron dysfunctions associated with aging (Kanning et al., 2010; Valdez et al., 2012) , suggesting that signaling related to excitability might be a central target of dysfunction in neurodegenerative conditions affecting MNs (Mentis et al., 2011; Imlach et al., 2012) .
Contrary to some (Ravikumar et al., 2004) , but not all (Zhang et al., 2011; Kim et al., 2012; Selvaraj et al., 2012) previous studies on the role of mTOR signaling in neurodegeneration, our results provide evidence that mTOR activity is critically important to delay disease progression in FALS. mTOR-dependent accumulation of the potent neuroprotective gene Btg2, a calcium-induced transcriptional coregulator, suggests that mTOR signaling might be required to boost compromised neuroprotective signaling pathways in FALS MNs, thereby synergizing with excitability signaling (Greer and Greenberg, 2008; Zhang et al., 2009; Hardingham and Bading, 2010) (Figures 8F and 8G) . Enhancing MN excitability was sufficient to reverse Btg2 upregulation, suggesting that a protective mTOR-Btg2 pathway is augmented in FALS MNs upon a deficit in neuroprotective signaling through excitability. Given that Rapamycin appears to be protective in some neurodegenerative settings (e.g., by relieving a brake on autophagy), the mTOR pathway might provide neuroprotection specifically within certain disease contexts including FALS, but might interfere with neuroprotection in a different subset of disease contexts. Our findings further suggest that although misfSOD1 accumulation is a valuable biomarker of disease (Bosco et al., 2010) (Figure 8G ), it might not directly promote disease progression. Indeed, one interpretation consistent with our results is that misfSOD1 accumulation in MNs might be part of a cellular defense process to trap and neutralize dysfunctional components in larger aggregates (Arrasate et al., 2004) . The accumulation of misfSOD1 was most closely correlated to a deficit in excitability signaling in vulnerable FALS MNs (Piotrkiewicz and Hausmanowa-Petrusewicz, 2011), suggesting that mutSOD1 might interact and interfere with molecular components involved in neuronal excitability, e.g., proteins affecting calcium transport (Kikuchi et al., 2006; Urushitani et al., 2008; Rizzuto et al., 2012) .
Our observations that enhanced excitability and mTOR are critically important to provide neuroprotection in FALS MNs are consistent with the notion that altered calcium fluxes, e.g., through the ER might underlie the enhanced vulnerability of alpha-MNs in FALS mice (Sikló s et al., 1998; Langou et al., 2010) . Reduced ER calcium and elevated cytosolic calcium might reduce the excitability of FALS MNs due to hyperpolarization of the plasma membrane through calcium-dependent potassium currents, and inhibition of these currents might provide one mechanism through which C-boutons protect alpha-MNs in FALS. The larger C-boutons might augment calcium refilling in FALS alpha-MNs (Pullen and Athanasiou, 2009 ), e.g., through store-operated calcium entry involving ER membranes at C-boutons (Shen et al., 2011) , but voltage-gated calcium channel routes are also possible. Similar mechanisms relating calcium fluxes and excitability to neurodegeneration and neuroprotection might be relevant to other neurodegenerative diseases (Tu et al., 2006; Palop and Mucke, 2010; Gleichmann et al., 2012) . Thus, reduced ER calcium levels and calcium gradients across the ER as well as Calreticulin downregulation have also been related to disease in Alzheimer's, Parkinson's, and Huntington's disease (Taguchi et al., 2000; Kipanyula et al., 2012) . Furthermore, excitability and synaptic calcium entry have been related to neuroprotective signaling (Hardingham and Bading, 2010) .
In conclusion, our results provide insights into causal relationships between critical early disease-related dysfunctions and adaptive responses in FALS mice. We identify excitability signaling and a synaptic and molecular pathway leading to mTOR activation in alpha-MNs as critically important to provide neuroprotection in FALS MNs. More generally, our results provide evidence that a focus on endogenous neuroprotection pathways in presymptomatic mice can provide valuable and unbiased criteria to assess the potential of therapeutic strategies in neurodegeneration.
EXPERIMENTAL PROCEDURES
Mice, Reagents, and Pharmacological Treatments B6SJL-TgN(SOD1-G93A) dl 1Gur/J, referred to as slow (G93A-s), B6SJL-Tg(SOD1-G93A)1Gur/J, referred to as fast (G93A-f), and B6SJL-Tg(SOD1-G85R) were obtained from Jackson Laboratory. ChAT-CRE and PV-CRE mice were from S. Arber (Biozentrum and FMI). All experiments were carried out in male mice. Animal housing, care, and experimental procedures were conformed to Swiss Veterinary Law guidelines. Drug delivery regimes were based on published reports. In addition, doseresponse curves were established in FALS mice in order to avoid detectable toxicity ranges in the mutant mice (at least one order of magnitude below toxic dosages; see Supplemental Experimental Procedures). Drug delivery protocols in all mice were as follows. Methoctramine (Sigma): injected intraperitoneally (i.p.) in saline at 200 mg/kg; Salubrinal (Alexis Biochemicals; dissolved at 10 mg/ml in DMSO) injected i.p. in saline at 1 mg/kg; Oxotremorine M (Tocris Bioscience) injected i.p. in saline at 30-50 mg/kg; Rapamycin (Tocris Bioscience; dissolved in ethanol at 20 mg/ml) injected i.p. in adjuvant at 6 mg/kg; (RS)-AMPA hydrobromide (Tocris Bioscience) injected i.p. in saline (or in sweetened drinking water, at 6 nM/l) at 15-20 nM/25 gm (or 3 nM/l in sweetened drinking water for chronic treatments); CNQX at 20 mmol/l drinking water; Tunicamycin, Brefeldin, Thapsigargin (Ascent Scientific) injected i.p. in saline at 1 mg/g; Quizapine (Tocris) injected i.p. in saline at 0.3 mg/kg; 8OHDPAT (Tocris) injected subcutaneously (s.c.) in saline at 0.3 mg/kg; Ketanserin (Tocris) injected s.c. in saline at 5 mg/kg; and WAY100135 (Tocris) injected s.c. in saline at 5 mg/kg. For   pharmacogenetic experiments, pAAV(9)-CBA-GFP-2A-floxed-PSAM(L141F,Y115F)GlyR-WPRE at the titer of 6.3 3 10 13 and pAAV(9)-pCAG-A7-floxed-PSAM(L141F, Y115F)5HT3-WPRE at the titer of 9 3 10 13 were prepared by Vector BioLabs as described (Magnus et al., 2011) . A total of 1 ml of viral suspension was injected during 30 min with a glass capillary coupled to a Picospritzer-III apparatus in 8-10 ms pulses (Supplemental Experimental Procedures). The ligand JFRC-PSEM-0308 (kind gift of S. Sternson) was administered by daily i.p. injections at the dose of 5 mg/kg in saline, starting 5 days after viral injection.
Neuron Endogenous Neuroprotection Mechanisms in ALS
Immunocytochemistry and Antibodies
Mice were perfused with 4% PFA in PBS, (L3-L5) lumbar spinal cord or cerebellum was isolated and kept overnight at 4 C in 30% sucrose. After embedding, 50 mm cryostat sections were post fixed with 4% PFA for 10 min, followed by PBS washes. Antibodies (Supplemental Experimental Procedures) were applied in PBS with 3% BSA, 0.3% Triton X-100, and incubated either overnight or for 3 days at 4 C. Sections were then briefly washed with PBS and incubated for 120 min at room temperature with appropriate combinations of secondary antibodies from Invitrogen.
Imaging and Image Analyses
Confocal images were acquired using a Leica SP5 (Leica Microsystems), fitted with a 203 air objective, Olympus Fluoview (Olympus, Tokyo) microscope, fitted with a 103 or 203 air objective, or an LSM Meta (Carl Zeiss AG) microscope, fitted with a 403 oil objective. Images were processed using Imaris software (Supplemental Experimental Procedures). For the analysis of BiP or misf-SOD1 labeling intensities, data were acquired using identical confocal settings, ensuring that signals at the brightest cells were not saturated and that background levels outside MN pools were still detectable. Images were analyzed quantitatively using Image-Pro 5 software (Media Cybernetics). Signal intensities were measured at several regions within areas inside cells (at least three regions per cell), excluding areas lacking signal; average intensities were calculated and background levels outside cells were subtracted from these values. For the calculation of MN percentages expressing misf-SOD1, BiP, P i -eIF2a, or p-S6, double positive MNs (MN markers were ChAT or VAChT) and signal intensity values for the antigen of interest were calculated over 15-20 spinal sections in triplicate animals (Supplemental Experimental Procedures).
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